SEREVENT

This brand name is authorized in United States. It is also authorized in Australia, Austria, Brazil, Canada, Croatia, Cyprus, Estonia, Finland, France, Germany, Hong Kong SAR China, Ireland, Israel, Italy, Japan, Lithuania, Malta, Mexico, Netherlands, New Zealand, Poland, South Africa, Spain, Turkey, UK.

Active ingredients

The drug SEREVENT contains one active pharmaceutical ingredient (API):

1	Salmeterol UNII 6EW8Q962A5 - SALMETEROL XINAFOATE
	Salmeterol is a selective long-acting (12 hour) β2 adrenoceptor agonist. These pharmacological properties of salmeterol offer more effective protection against histamine-induced bronchoconstriction and produce a longer duration of bronchodilation, lasting for at least 12 hours, than recommended doses of conventional short-acting β2 agonists.
	Read more about Salmeterol

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
SEREVENT DISKUS Inhalation powder	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
R03AC12	Salmeterol	R Respiratory system → R03 Drugs for obstructive airway diseases → R03A Adrenergics, inhalants → R03AC Selective beta-2-adrenoreceptor agonists
Discover more medicines within R03AC12

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	8141L
BR	Câmara de Regulação do Mercado de Medicamentos	510607104170318
CA	Health Products and Food Branch	02231129
DE	Bundesinstitut für Arzneimittel und Medizinprodukte	00013468, 00013474, 00148903, 00148926, 04650769, 05541746, 05702600, 05702623, 06118702, 06118719, 06468945, 06468951, 07320297, 07533030, 07533076, 08652498, 09707385, 11018397, 11692863, 11697694, 11861900, 11861917, 12453037, 12453043, 13624860, 13624877, 13867060
EE	Ravimiamet	1000405, 1007907
ES	Centro de información online de medicamentos de la AEMPS	59489, 59490
FI	Lääkealan turvallisuus- ja kehittämiskeskus	115931
FR	Base de données publique des médicaments	67274478, 69163238
GB	Medicines & Healthcare Products Regulatory Agency	100731, 139979, 147061, 147064, 162418, 162420, 186117, 33810, 368954, 374156, 377029
HK	Department of Health Drug Office	35936
HR	Agencija za lijekove i medicinske proizvode	HR-H-128359684, HR-H-899859080
IE	Health Products Regulatory Authority	36907, 59943, 72839
IL	מִשְׂרַד הַבְּרִיאוּת	3541, 6049
IT	Agenzia del Farmaco	027890146
JP	医薬品医療機器総合機構	2259708G3025
LT	Valstybinė vaistų kontrolės tarnyba	1001757, 1001758
MT	Medicines Authority	MA192/01002
MX	Comisión Federal para la Protección contra Riesgos Sanitarios	438M93
NL	Z-Index G-Standaard	13604627, 14039303
NL	Z-Index G-Standaard, PRK	32808, 45616
NZ	Medicines and Medical Devices Safety Authority	11643, 5495
PL	Rejestru Produktów Leczniczych	100088919, 100164566
TR	İlaç ve Tıbbi Cihaz Kurumu	8699522523245, 8699522553228
US	FDA, National Drug Code	0173-0520, 0173-0521
ZA	Health Products Regulatory Authority	29/10.2.1/0350, A40/10.2.1/0064